Ollin Biosciences
TX - AustinBiotechnology
Focus: Ollin Biosciences is an early-stage biotechnology company founded in 2023 focused on bispecific antibody development for therapeutic applications. The company is publicly listed but remains in very early clinical development with minimal commercial footprint.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About Ollin Biosciences
AI assessmentNot HiringNo open roles listed right now. Follow Ollin Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Faricimab
Diabetic Macular Edema (DME)Clinical Trials (1)
NCT07484074A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
Phase 1Help build intelligence for Ollin Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.